Thyroid Stimulating but Not Blocking Autoantibodies Are Highly Prevalent in Severe and Active Thyroid-Associated Orbitopathy: A Prospective Study

The clinical utility of the functional TSH receptor autoantibodies was prospectively evaluated in patients with thyroid-associated orbitopathy (TAO). Ophthalmic, endocrine, and serological investigations were performed in 101 consecutive patients with severe and active TAO. Serum thyroid stimulating...

Full description

Saved in:
Bibliographic Details
Main Authors: E. Kampmann, T. Diana, M. Kanitz, D. Hoppe, G. J. Kahaly
Format: Article
Language:English
Published: Wiley 2015-01-01
Series:International Journal of Endocrinology
Online Access:http://dx.doi.org/10.1155/2015/678194
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832549322734960640
author E. Kampmann
T. Diana
M. Kanitz
D. Hoppe
G. J. Kahaly
author_facet E. Kampmann
T. Diana
M. Kanitz
D. Hoppe
G. J. Kahaly
author_sort E. Kampmann
collection DOAJ
description The clinical utility of the functional TSH receptor autoantibodies was prospectively evaluated in patients with thyroid-associated orbitopathy (TAO). Ophthalmic, endocrine, and serological investigations were performed in 101 consecutive patients with severe and active TAO. Serum thyroid stimulating (TSAb) and blocking (TBAb) antibody levels were measured with two bioassays using cells that express a chimeric TSH receptor and CRE-dependent luciferase. TSAb results are expressed as percentage of specimen-to-reference ratio (SRR %). Blocking activity is defined as percent inhibition of luciferase expression relative to induction with bovine TSH alone. All 101 consecutively followed-up patients with severe and active TAO were TBAb negative. In contrast, 91 (90%) were TSAb positive of whom 90 had Graves’ disease. Serum TSAb levels correlated with the diplopia score (P=0.016), total severity eye score (P=0.009), proptosis (P=0.007), lid aperture (P=0.003), upper lid retraction (P=0.006), keratopathy (P=0.04), and thyroid binding inhibiting immunoglobulins (TBII, P<0.001) and negatively with the duration of TAO (P=0.002). Median serum values of TSAb were SRR% 418 (range 28% to 795%). TSAb, not TBAb, are highly prevalent in severe/active TAO and serum TSAb levels correlate with clinical disease severity.
format Article
id doaj-art-9fd67a9c5d5f4826922d4c16df60e991
institution Kabale University
issn 1687-8337
1687-8345
language English
publishDate 2015-01-01
publisher Wiley
record_format Article
series International Journal of Endocrinology
spelling doaj-art-9fd67a9c5d5f4826922d4c16df60e9912025-02-03T06:11:41ZengWileyInternational Journal of Endocrinology1687-83371687-83452015-01-01201510.1155/2015/678194678194Thyroid Stimulating but Not Blocking Autoantibodies Are Highly Prevalent in Severe and Active Thyroid-Associated Orbitopathy: A Prospective StudyE. Kampmann0T. Diana1M. Kanitz2D. Hoppe3G. J. Kahaly4Molecular Thyroid Research Laboratory, Johannes Gutenberg University (JGU) Medical Center, 55131 Mainz, GermanyMolecular Thyroid Research Laboratory, Johannes Gutenberg University (JGU) Medical Center, 55131 Mainz, GermanyMolecular Thyroid Research Laboratory, Johannes Gutenberg University (JGU) Medical Center, 55131 Mainz, GermanyDepartment of Psychology, Technical University of Darmstadt, 64283 Darmstadt, GermanyMolecular Thyroid Research Laboratory, Johannes Gutenberg University (JGU) Medical Center, 55131 Mainz, GermanyThe clinical utility of the functional TSH receptor autoantibodies was prospectively evaluated in patients with thyroid-associated orbitopathy (TAO). Ophthalmic, endocrine, and serological investigations were performed in 101 consecutive patients with severe and active TAO. Serum thyroid stimulating (TSAb) and blocking (TBAb) antibody levels were measured with two bioassays using cells that express a chimeric TSH receptor and CRE-dependent luciferase. TSAb results are expressed as percentage of specimen-to-reference ratio (SRR %). Blocking activity is defined as percent inhibition of luciferase expression relative to induction with bovine TSH alone. All 101 consecutively followed-up patients with severe and active TAO were TBAb negative. In contrast, 91 (90%) were TSAb positive of whom 90 had Graves’ disease. Serum TSAb levels correlated with the diplopia score (P=0.016), total severity eye score (P=0.009), proptosis (P=0.007), lid aperture (P=0.003), upper lid retraction (P=0.006), keratopathy (P=0.04), and thyroid binding inhibiting immunoglobulins (TBII, P<0.001) and negatively with the duration of TAO (P=0.002). Median serum values of TSAb were SRR% 418 (range 28% to 795%). TSAb, not TBAb, are highly prevalent in severe/active TAO and serum TSAb levels correlate with clinical disease severity.http://dx.doi.org/10.1155/2015/678194
spellingShingle E. Kampmann
T. Diana
M. Kanitz
D. Hoppe
G. J. Kahaly
Thyroid Stimulating but Not Blocking Autoantibodies Are Highly Prevalent in Severe and Active Thyroid-Associated Orbitopathy: A Prospective Study
International Journal of Endocrinology
title Thyroid Stimulating but Not Blocking Autoantibodies Are Highly Prevalent in Severe and Active Thyroid-Associated Orbitopathy: A Prospective Study
title_full Thyroid Stimulating but Not Blocking Autoantibodies Are Highly Prevalent in Severe and Active Thyroid-Associated Orbitopathy: A Prospective Study
title_fullStr Thyroid Stimulating but Not Blocking Autoantibodies Are Highly Prevalent in Severe and Active Thyroid-Associated Orbitopathy: A Prospective Study
title_full_unstemmed Thyroid Stimulating but Not Blocking Autoantibodies Are Highly Prevalent in Severe and Active Thyroid-Associated Orbitopathy: A Prospective Study
title_short Thyroid Stimulating but Not Blocking Autoantibodies Are Highly Prevalent in Severe and Active Thyroid-Associated Orbitopathy: A Prospective Study
title_sort thyroid stimulating but not blocking autoantibodies are highly prevalent in severe and active thyroid associated orbitopathy a prospective study
url http://dx.doi.org/10.1155/2015/678194
work_keys_str_mv AT ekampmann thyroidstimulatingbutnotblockingautoantibodiesarehighlyprevalentinsevereandactivethyroidassociatedorbitopathyaprospectivestudy
AT tdiana thyroidstimulatingbutnotblockingautoantibodiesarehighlyprevalentinsevereandactivethyroidassociatedorbitopathyaprospectivestudy
AT mkanitz thyroidstimulatingbutnotblockingautoantibodiesarehighlyprevalentinsevereandactivethyroidassociatedorbitopathyaprospectivestudy
AT dhoppe thyroidstimulatingbutnotblockingautoantibodiesarehighlyprevalentinsevereandactivethyroidassociatedorbitopathyaprospectivestudy
AT gjkahaly thyroidstimulatingbutnotblockingautoantibodiesarehighlyprevalentinsevereandactivethyroidassociatedorbitopathyaprospectivestudy